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Abstract
Purpose: The development of resistance against anticancer drugs has been a persistent clinical problem for the
treatment of locally advanced malignancies in the head and neck mucosal derived squamous cell carcinoma
(HNSCC). Recent evidence indicates that the DNA translesion synthesis (TLS) polymerase η (Pol η; hRad30a gene)
reduces the effectiveness of gemcitabine/cisplatin. The goal of this study is to examine the relationship between the
expression level of Pol η and the observed resistance against these chemotherapeutic agents in HNSCC, which is
currently unknown.
Methods: Sixty-four mucosal derived squamous cell carcinomas of head and neck (HNSCC) from 1989 and 2007 at
the City of Hope National Medical Center (Duarte, CA) were retrospectively analyzed. Pretreatment samples were
immunostained with anti-Pol η antibody and the correlation between the expression level of Pol η and clinical
outcomes were evaluated. Forty-nine cases treated with platinum (n=40) or gemcitabine (n=9) based chemotherapy
were further examined for Pol η expression level for comparison with patient response to chemotherapy.
Results: The expression of Pol η was elevated in 67% of the head and neck tumor samples. Pol η expression level
was significantly higher in grade 1 to grade 2 tumors (well to moderately differentiated). The overall benefit rate
(complete response+ partial response) in patients treated with platinum and gemcitabine based chemotherapy was
79.5%, where low Pol η level was significantly associated with high complete response rate (p=0.03), although not
associated with overall survival. Furthermore, no significant correlation was observed between Pol η expression level
with gender, age, tobacco/alcohol history, tumor stage and metastatic status.
Conclusions: Our data suggest that Pol η expression may be a useful prediction marker for the effectiveness of
platinum or gemcitabine based therapy for HNSCC.
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Introduction
Mucosal derived squamous cell carcinoma of the head and
neck (HNSCC) refers to a group of biologically similar cancers
originated from the mucosal squamous epithelial lining of upper
aerodigestive tract, including the lip, oral cavity, nasal cavity,
paranasal sinuses, pharynx, and larynx. HNSCC is the sixth
most frequently occurring cancer worldwide and accounts for
2% of all cancer death annually. According to the American
Cancer Society, 36,540 Americans were diagnosed with head
and neck cancer in 2011 and 7,880 died from the disease [1,2].
Most patients present lymph node metastatic disease at the
time of diagnosis, and the five-year survival rate of those
patients is around 35% [3]; which has not improved over the
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last decade [4]. Platinum-based combination regimen, such as
cisplatin/oxaliplatin plus 5-FU and taxotere, is the current first-
line neoadjuvant chemotherapy for locally advanced HNSCC
[22]. However, the poor or partial response to platinum-based
chemotherapy of HNSCC remains an enigma for oncologists.
Platinum compounds form DNA intrastrand or interstrand
cross-links that severely block DNA synthesis and result in
mutations and apoptosis [5]. These platinum induced adducts
are repaired by nucleotide excision repair system (NER) [6,7],
the mismatch repair (MMR) system, and recombination repair
(RR) [8]. In addition, DNA translesion synthesis (TLS)
polymerases have also been shown to have the ability to
bypass cisplatin-induced intrastrand adducts [9,11,39,40]. This
suggests these bypass polymerases provide an alternate
mechanism in handling platinum compound induced DNA
adducts and may contribute to the observed resistance against
these compounds [9,11]. Among the TLS DNA polymerases,
DNA Polymerase η (Pol η; hRad30a gene; xeroderma
pigmentosum variant gene product) is the only one with well-
understood biological function, which is to replicate across the
cis-syn cyclobutane pyrimidine dimers (CPDs) that induced by
UV radiation [10]. Genetic defects in the gene encoding Pol η
results in Xeroderma Pigmentosum Variant (XP-V) disease,
and XP-V patients are highly sensitive to UV irradiation and
prone to the development of skin cancer [10]. Pol η has also
been shown to have the ability to bypass a broad range of DNA
lesions, such as 7,8-dihydro-8-oxoguanine [15], (+]-trans-anti-
benzo[α]pyrene-N2-dG [16], acetylaminofluorene-adducted
guanine [17], O6-methylguanine [18], and thymine glycol [41].
In addition, it has been demonstrated that Pol η can
modulate the cellular sensitivity to chemotherapeutic agents
[11]. The Pol η deficient cells derived from XP-V patients were
more sensitive to β-D-arabinofuranosylcytosine (cytarabine,
araC), gemcitabine, and cisplatin [12]. Cellular and biochemical
analyses suggested that the higher sensitivity of XP-V cells to
these agents is due to the lack of Pol η activity in facilitating the
resumption of the paused DNA replication caused by
therapeutic agents [13,14]. Pol η bypasses the Pt-GG
intrastrand crosslinked adducts with a relative higher efficiency
and fidelity, as comparing to other TLS enzymes [42-44].
Studies have also demonstrated that the expression level of
Pol η negatively correlated with cisplatin sensitivity of non-small
cell lung cancer (NSCLC) cell lines [19]. Furthermore, Pol η
protein expression was suggested to be an independent
predictive marker for the treatment response and survival of
metastatic gastric adenocarcinoma patients who are treated
with oxaliplatin-based chemotherapy [20].
In this study, we examined the associations between in situ
expression of Pol η proteins and known prognostic factors
including staging and tumor differentiation. We also examined
the associations between expression of Pol η proteins and
response to platinum or gemcitabine based chemotherapy
treatment and survival in HNSCC.
Materials and Methods
Patient characteristics
Tumor blocks for sixty-four patients diagnosed with mucosal
derived squamous cell carcinomas of head and neck (HNSCC)
from 1989 and 2007 at the City of Hope National Medical
Center (Duarte, CA) were retrospectively analyzed. Tumor
blocks included tumors of the nasopharynx, paranasal sinuses,
oral cavity, oropharynx, hypopharynx, and larynx. The median
age of the patients was 59 years (range 39–78 years) at the
time of diagnosis. Eight patients were excluded for survival
analysis due to the lack of long term follow-up studies. The
median follow-up period was 56 months (range, 4.3–142
months). Among the 64 patients, 51 were primary HNSCC and
13 were recurrent or second primary tumor. Thirty-four patients
underwent radical surgery, 49 patients received chemotherapy
(40 patients received neoadjuvant cisplatin, taxotere and 5-FU,
4 patients also received gemcitabine, and the remaining 5 of
the inoperable recurrent cancer patients received palliative
chemotherapy (gemcitabine and hydroxyurea). Details of the
clinic characteristics are summarized in Table 1.
All patients’ information and tissue sample collection were
approved by the IRB committee (protocol# 95917) at City of
Hope National Medical Center and the Beckman Research
Institute, CA. Information regarding clinical outcome and
response to chemotherapy was obtained from hospital chart
review and clinical protocol record. Patients were staged
according to the TNM classification system from American
Joint Committee on Cancer (AJCC). Disease free survival was
defined as the time from the date of confirmed diagnosis to last
contact date and censored at the recurrent date. Squamous
cell carcinoma was graded using Anneroth's multi-factorial
grading system: G1-well differentiated, G2-moderately
differentiated, G3-poorly differentiated, G4-undifferentiated.
Clinical response to chemotherapy were evaluated by tumor
size reduction and neck lymph node status on the computed
tomography scan before and after chemotherapy, according to
Response Evaluation Criteria in Solid Tumors (RECIST criteria)
[21] as follows: complete response (CR)= 100% regression of
the disease; partial response (PR), ≥30% decrease in the sum
of the longest diameter of the targets; progressive disease≥
20% increase; and stable disease (SD)= the remainders.
Pathological complete response (pCR) was defined as
absence of any gross or microscopic evidence of residual
tumor in the surgical or biopsy specimen following
chemotherapy. Since the pCR was only observed in four
patients, therefore, only the clinical response was used for
statistical analysis.
Tissue samples and antibody
HNSCC samples (n= 64) and paracancer normal squamous
mucosal tissues prior to chemotherapy were obtained from
patients undergoing operation for carcinoma resection or
incisional/excisional biopsy with written informed consent of
patients from January 1989 to June 2007. Nine out of sixty-four
post-chemo tumor tissues were also compared. Histological
grading was assessed according to the 1987 International
Union against Cancer (UICC). The anti-Pol η antibody was
Polymerase η in Head and Neck Cancer Chemotherapy
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generated by immunizing rabbit with highly purified N-terminal
domain of human Pol η protein (amino acid 1 to 513, see
Figure 1a). The polyclonal antibody was purified using a G
protein column. Antibody specificity was evaluated with
western blotting and blocking assay (Figure 1b and 1c).
Western blot analysis
Western blot was conducted as previously described [1].
Briefly, 20-μg of total cell lysate was separated by 10% SDS-
PAGE before transferred to a nitrocellulose membrane (Bio-
Rad Laboratories, CA) and incubated with blocking buffer (1%
Table 1. Clinicopathological parameters and Pol η
expression in 64 HNSCC.
Characteristic n POLη staining P a
  Low (%) High (%)  
Age (yrs)       
<59 33 12 36 21 64  
≥60 31 9 29 22 71 0.73
Gender       
Female 17 5 29 12 71  
Male 47 16 34 31 66 0.34
T stageb,c       
T1 9 3 33 6 67  
T2 10 3 30 7 70  
T3 21 7 33 14 67  
T4 17 6 35 11 65 0.56
N statusb       
N− 7 2 29 5 71  
N+ 57 19 33 38 67 0.32
Histological differentiation       
Well 8 0 0 8 100  
Moderate 33 7 21 26 79  
Poor 23 14 61 9 39 0.01
Tobacco       
No 18 7 39 11 61  
Yes 46 14 30 32 70 0.63
EtOH       
No 44 16 36 28 64  
Yes 20 5 25 15 75 0.34
Chemotherapy       
No 16 4 25 12 75  
Yes 48 17 37 30 63 0.2
a Probability of statistical difference (P) was analyzed by χ2 test for independence.
b Patients were classified according to the American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) WHO grading system and by
the presence or absence of lymph node metastasis (N status).
c 7 patients' T stage could not be determined.
Data represented percentages of cases with low or high Pol η expression in each
parameter, and n represents absolute case number of each parameter. Probability
of statistical difference (P) was analyzed by χ2 test for independence. Patients
were classified according to the American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) WHO grading system and by the
presence or absence of lymph node metastasis (N status).
doi: 10.1371/journal.pone.0083978.t001
I-Block reagent and 0.1% Tween 20) containing Pol η primary
antibody overnight at 4°C. The membrane was washed with
PBS with 0.1% Tween 20 for 3-5 times before incubated with
fluorescent-labeled secondary antibodies for additional 60
minutes. After sequential washes, the signals on the
membranes were scanned with an Odyssey Infrared Imaging
System (LI-COR Biosciences) or detected using a Fuji
LAS-1000 imaging system.
Immunohistochemistry
Human GM637 wild type and the Pol η deficient XP30RO
cells were used to validate the antibody developed in the
laboratory. Briefly, the proliferative cells were fixed with 4%
paraformahyde in PBS followed by incubation with
permeabilization buffer (0.5% saponin, 0.1% BSA and 0.1%
NaN3 in PBS) at room temperature for 30 min before the
addition of primary antibodies to the permeabilization buffer for
additional 1 h at room temperature. The primary antibodies
were removed by washing the cells three times with
permeabilization buffer before the addition of DyLight 488 or
DyLight 549 conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, Inc.) for additional 1 h. The
cells were examined using confocal microscopy (Biorad).
For the expression of Pol η in paraffin-embedded tissue
blocks obtained from patients, immunohistochemical staining
was performed using 4-μm thick sections prepared from
formalin fixed blocks. Tissue sections were deparaffinized in
xylene followed by 100% ethanol. Samples were then
quenched in 3% hydrogen peroxide and pretreated to promote
antigen retrieval by steaming with EDTA solution. After antigen
retrieval, slides were incubated in Protein Block (DAKO,
Carpinteria, CA) for 5 minutes followed by incubation with
primary anti-Pol η antibodies for 30 minutes at room
temperature. The slides were then washed in Dako buffer and
incubate with DAKO Envision with anti-rabbit Polymer
secondary antibody (DAKO, Carpinteria, CA) for additional 30
minutes. After washes in Dako buffer, slides were incubated
with the chromogen diaminobenzidine tetrahydrochloride (DAB,
Sigma-Aldrich, St. Louis, MO), counterstained with
hematoxylin, and mounted.
The staining of Pol η was evaluated by counting of positive
nuclear stained cells. In general, the staining of Pol η was
crisp, with minimal background staining of paratumor stromal
cells as shown in Figure 1. A total of 20 high power fields were
counted for each samples, and the percentage of positive
tumor cell nuclei was counted for each case (magnification
×400, field size 0.18 mm2) in areas with most positive nuclei
(hot spots). Nuclear immunoreactivity was scored based on the
staining intensity and staining extent, and was graded using a
two tier grading system: low expression: nuclear staining in
<30% tumor cells; and high expression: nuclear staining in
>30% tumor cells. All cases were scored blindly by three
observers and showed an inter-rater reliability (intra-class
Correlation Coefficient, Cronbach's α = 0.82).
Statistical Analysis
The relationship between Pol η expression and
clinicopathological characteristics was examined by a chi-
Polymerase η in Head and Neck Cancer Chemotherapy
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Figure 1.  Generation and validation of anti-Pol η antibody.  A) The N-terminal fragment of Pol η (highlighted in grey) used for
the generation of an anti-Pol η antibody. B) The developed antibody used for the detection of Pol η in the lysates derived from
GM637 or XP30RO cells. C) Lane 1. Identification of Pol η from the lysate from human HCT116 cells. Lane 2. Blocking with purified
recombinant human Pol η protein. D) 1-3, GM 637 cells probed with secondary antibody alone (D2 and D3). 4-6, GM637 cells
probed with anti-Pol η antibody (D5) or anti-PCNA antibody (D6). 7-9, XP30RO cells probed with anti-Pol η antibody (D8) or anti-
PCNA antibody (D9).
doi: 10.1371/journal.pone.0083978.g001
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square test and Fisher's exact tests. Univariate analysis of
disease free survival was done by Kaplan-Meier analysis (log-
rank test). Multivariate analysis was carried out with Cox's
proportional hazard model adjusting for major clinicopathologic
parameters. The P values (two-sided) less than 0.05 were
considered as statistical significance. All data was analyzed
using the JMP statistical software, Version 9 (Cary, NC).
Results
Validation of anti-Pol η antibody
The anti-Pol η antibody was developed by immunizing the
rabbit with highly purified human Pol η polymerase domain
within the N-terminal (1-513 amino acids, Figure 1a), the
detailed procedures were described in the Materials and
Methods. To test the specificity of the developed antibody, we
used this antibody to probe the presence of Pol η using cell
lysates from the human fibroblast GM637 cells or the XP30RO
fibroblast cells derived from XP-V patients. As shown in Figure
1b, the antibody recognized a ~80 kDa protein from the GM637
cell lysates that matches with the molecular weight of Pol η but
the same protein band was not detected in the XP30RO cell
lysates. To further this result, a competition assay using a
highly purified N-terminal fragment of Pol η to compete with the
endogenous cellular Pol η was also performed. As shown in
Figure 1c, the anti-Pol η antibody specifically recognized a
dominant protein band at ~80 kDa, which is consistent with the
molecular weight of Pol η. In the competition assay (Figure 1c,
lane 2), this recognized protein band was completely blocked
by the purified human Pol η, indicating the developed anti-Pol η
antibody has a high specificity to recognize human Pol η. To
further confirm the specificity of this antibody, we performed an
IHC study using wild type human GM637 and XP30RO
fibroblast cells derived from a XP-V patient. As shown in Figure
1D 5, the anti-Pol η antibody recognized Pol η in the nuclei of
GM637 cells but not in the Pol η deficient XP30RO cells
(Figure 1D 8). As internal control, anti- proliferating cell nuclear
protein (PCNA) signals were positive in both cells (Figure 1D. 6
and 9). No signals were detected when only secondary
antibody was present (Figure 1D 2-3). These results further
confirmed the specificity of anti- Pol η antibody.
Expression of Pol η was positively associated with
differentiation in HNSCC
The relationship between clinicopathological parameters and
Pol η expression was investigated and the results were listed in
Table 1. A significant correlation was observed between the
expression of Pol η and histological grade in HNSCC (p <0.01).
In addition, the percentages of Pol η-high expression level was
found to be correlated with the differentiation of HNSCC from
poor, moderated to well, as the percentages of Pol η-high
expression level were 39, 79, and 100%, respectively. Other
clinicopathological parameters including age of patients at
diagnosis, gender, T stage, N stage and tobacco/alcohol
history were also evaluated, but no statistical significance was
observed.
Immunostaining of Pol η in normal squamous epithelial
tissue and HNSCC
The Pol η expression level in HNSCC tissue was compared
to the noncancerous mucosal squamous epithelium (Figure 2).
As shown, Pol η is present in the basal and parabasal layers of
the normal squamous epithelium. In the interstitial tissue, only
trace amount of Pol η was detected in the stromal cells. A high
Pol η expression was observed in the germinal centers, which
is consistent with previous studies and its role in somatic
hypermutation in germinal center [45-47]. In comparison with
the normal squamous epithelium, an increased level of Pol η
expression was observed in the head and neck squamous cell
carcinomas as 43 of 64 carcinomas (67%) samples showed
positive stain. Squamous carcinoma cellular differentiation is a
characteristically most discernable as the presence or absence
of keratinization. Keratinization takes place in the form of
keratin pearls and is gathered toward the center of carcinoma
cell nests. The carcinoma cells in the center often exhibit an
increased differentiation phenotype than the edges of the nests
[55]. Although Pol η staining was higher in well-differentiated
carcinoma, no preferential localization of Pol η in the tumor
nests was observed [23]. The expression level of Pol η in
carcinoma cells that metastasized to the lymph nodes was also
examined and similar expression level was observed as
comparing to the corresponding primary sites (Figure 2).
Another interesting observation was that the mitotic cancer
cells showed low Pol η expression, which was consistent with
the fact that Pol η is mainly required during G1/S phase
[48-50].
Alteration of Pol η protein levels in response to
platinum based-chemotherapy
To determine whether platinum based chemotherapy altered
Pol η expression level, samples from the same HNSCC
patients pre- and post-chemotherapy were analyzed and
compared (n=9, Figure 3 and Table 2). We found 6/9 HNSCC
(67%) had similar or increased expression of Pol η after
chemotherapy (including one case that was nearly negative in
Pol η expression before chemotherapy) and 3/9 (33%) have
decreased Pol η expression after chemotherapy. The effect of
chemotherapy was evaluated by both tumor size reduction in
radiographical examination and histological examination of the
removed carcinoma tissue post treatment. The outcome of
chemotherapy was categorized as complete remission (CR),
partial response (PD), stable disease (SD) and progression
disease (PR). Data indicated that 33% CR (2 cases), 50% PR
(3 cases) and 17% PD/SD (1 case) showed similar up-
regulated Pol η expression post chemotherapy, and 33% CR (1
case), 67% PR (2 cases) and 0% PD showed decreased Pol η
expression. However, no significant correlation between the
expression change of Pol η in response to chemotherapy,
mainly due to the small sample size.
Clinical Significance of Pol η Staining Level in HNSCC
Previous studies have indicated that the basal Pol η
expression before treatment may affect the outcome of
platinum compounds based chemotherapy [19,20]. Therefore,
the association between the expression of Pol η before
Polymerase η in Head and Neck Cancer Chemotherapy
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treatment and clinical outcomes including chemotherapy
response and patient survival were examined. As shown in
Table 3, in the 12 subjects who achieved complete remission
(CR), 8 subjects (66%) had negative/low expression of Pol η,
and only 4 subjects (33%) showed high Pol η staining. In the
contrary, in the 10 subjects who failed to respond (PD+SD), 8
Figure 2.  The expression of Pol η protein in head and neck squamous cell cancer.  A) Nuclear staining of Pol η in normal
squamous epithelium as control. B) Comparison of Pol η staining level between HNSCC and para-cancer normal squamous
mucosa in oral cavity. C-E) HNSCC nuclear Pol η expression was classified as negative (C), low (D) and high, according to the
frequency and intensity of the stained cells. F-G) Comparison of Pol η staining in primary cancer in soft palate (F) and metastatic
cancer cells to lymph node (G). (Immunoperoxidase, original magnification: ×100 (A-B), ×200 (C-G)).
doi: 10.1371/journal.pone.0083978.g002
Figure 3.  Platinum-based chemotherapy and Pol η protein expression in head and neck squamous cell cancer.  Upper row
represents nuclear staining of Pol η in HNSCC before chemotherapy. Lower row represents Pol η staining in tissue obtained from
the same areas of original tumors after chemotherapy. Case 1) Pol η staining level up-regulated post chemotherapy. Case 2) Pol η
staining level down-regulated post treatment. Case 3-4) Pol η staining level remained same intensity post treatment
(immunoperoxidase, original magnification x200).
doi: 10.1371/journal.pone.0083978.g003
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were from high Pol η staining group (80%), only 2 subjects had
low Pol η staining (20%).
The relationship between disease specific survival and the
expression level of Pol η was further analyzed using Kaplan-
Meier analysis (log-rank test). Although there is a trend
Table 2. Regulation of Pol η protein expression level post
chemotherapy.
 CR a (%) PR a (%) PD+SD a (%) n P
up-regulation of Pol η 2 33 3 50 1 17 6  
down-regulation of Pol η 1 33 2 67 0 0 3 N/A
a CR, complete response; PR, partial response; SD, stable disease; PD,
progression disease.
doi: 10.1371/journal.pone.0083978.t002
Table 3. Association between Pol η protein expression and
clinical response to chemotherapy.
 Cases Pol η low (%) Pol η high (%) P value
CR a 12 8 (66) 4 (33)  
PR 27 8 (30) 19 (70)  
PD+SD 10 2 (20) 8 (80) 0.03
a CR, complete response; PR, partial response; SD, stable disease; PD,
progression disease. Details are explained in M&M.
doi: 10.1371/journal.pone.0083978.t003
showing that patients with high Pol η expression tend to have
shorter survival, the correlation was not significant (Figure 4).
Multivariate analysis was further performed with Cox's
proportional hazard model adjusting for major clinicopathologic
parameters. As shown in Table 4, T stage (P= 0.03) was the
only parameter found to be a significant independent predictor
of death from carcinomas. No other variables including Pol η
staining, age, N status, and histological tumor differentiation
were associated with survival according to the multivariate
analysis. The lack of association between Pol η expression and
patient survival in our study could be due to the small sample
size collected over a very long period. High local recurrence
rate is a well-known factor precluding long-term tumor-free
survival of the patients with HNSCC [2-4,22]. In our cohort,
there were 23 out of 64 patients died of disease recurrence,
including 16 patients with high Pol η level and 7 patients with
low Pol η level. However, no statistical significance was found
between Pol η expression and cancer recurrence (p= 0.15,
data not shown).
Discussion
It is known that platinum-based anticancer agents inhibit
tumor growth mainly by forming DNA adducts [50]. The high
expression level of Pol η has been correlated with poor clinical
outcome when platinum-based agents were used for the
management of non-small-cell lung cancer and metastatic
gastric adenocarcinoma [19,20]. According to the Human
protein atlas project, Pol η is ubiquitously expressed in nuclei in
Figure 4.  Kaplan-Meier survival probability comparing tumors with high Pol η expression to those with low Pol η
expression.  The blue curve corresponds to patients with high Pol η level and the red curve to patients with low Pol η level.
doi: 10.1371/journal.pone.0083978.g004
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essentially most tissues except the mesenchymal-, glial- and
stromal cells in endocrine tissues [28]. In addition, Pol η has
been observed in most carcinoma cells, although different
expression levels have been reported [19,20,28,29]. Therefore,
the potential impact of Pol η on the activity of platinum-based
drugs or gemcitabine in HNSCC is examined in this report.
In this study, we observed that Pol η was mainly expressed
in the highly proliferating basal and parabasal layers of normal
mucosal squamous epithelium. A much higher expression level
of Pol η expression was detected in the majority of HNSCC as
compared to the normal counterpart tissues. In addition, a
higher Pol η expression level in well-differentiated HNSCC was
detected as compared to poorly-differentiated ones (Figure 2
and Table 1). We also observed that high basal level of Pol η
expression before chemotherapy is significantly correlated to
the low response rate to chemotherapy. In previous studies, it
has been shown that Pol η reduces the cytotoxic effects of both
gemcitabine and cisplatin by extending DNA with gemcitabine
at the 3’ termini [11] or bypassing cisplatin-induced intrastrand
adducts [13]. In our cohort, only 5 patients received
gemcitabine single treatment and 4 patients received both
cisplatin and gemcitabine treatments. We combined these 9
cases with 40 cases treated with cisplatin for analysis. Patients
with low basal expression of Pol η had a higher rate of
complete response (8/18) than those who have high basal Pol
η expression (4/31) (p=0.03) (Table 3). Our data further
supported that bypass activity of Pol η affects platinum/
gemcitabine activity in the management of HSCCC, and the
expression level of Pol η may be useful for the prediction of a
clinic response before chemotherapy. The overall benefit rate
(CR+PR) was not significantly different in these two groups of
patients (16/18 in Pol η low group and 23/31 in Pol η high
group) (data not shown), which mainly was due to high partial
response rate (18/31) in Pol η high group. This could be due to
the activity of other DNA repair mechanisms contributing to the
overall sensitivity to chemotherapeutic agents in tumor tissues
Table 4. Contribution of various potential prognostic factors
to disease-free survival in oral carcinoma patients (n = 58).
Parameters Risk ratio 95% CIa Pb
Age 2.71 0.85-10.22 0.09
T stage 3.47 2.17-6.98 0.03
N status 1.04 0-4.39 0.23
Histological differentiation 2.98 0.72-14.8 0.12
POL η staining 0.9 0.20-3.92 0.86
chemotherapy 0.79 0.08-17.62 0.85
Tobacco 2.24 0.54-11.4 0.32
EtOH 1.42 0.61-3.39 0.26
a CI, confidence interval.
b P value was obtained by Cox proportional hazards method. Calculated by log-
rank test.
doi: 10.1371/journal.pone.0083978.t004
[24-27]. For examples, DNA nuclear excision repair proteins
and BRCA1 were reported to contribute to resistance against
platinum-based agents [35-38,51-54].
Previous studies have demonstrated that cisplatin treatment
elevated expression of DNA repair genes and contributed to
the observed resistance [30-34]. Ceppi et. al. reported that Pol
η mRNA levels in non-small cell lung cancer (NSCLC) cell lines
were significantly induced by cisplatin [19]. A previous cellular
study has shown that the downregulation of DNA lesion bypass
polymerase ζ (Pol ζ) in the head and neck squamous
carcinoma cells sensitizes cells to cisplatin, and inhibition of
hRev3 gene expression was suggested to be a potential
clinical strategy to reducing resistance against cisplatin in
HNSCC [56]. In this study, we observed that the expression
level of Pol η level increased in 6 cases (6/9) of the 9 patients
who were resistant to platinum or gemcitabine based
chemotherapy, which has not been reported before. Further
studies will be necessary with a larger sample size to conclude
whether the alteration of Pol η expression before and after
chemotherapy could be used as a predictor for development of
resistance to platinum or gemcitabine based chemotherapy.
Our current study indicated that a high level expression of
Pol η is associated with a reduced sensitivity to platinum/
gemcitabine treatment, suggesting that expression level of Pol
η can be used as a predictive marker. Our current results also
indicate that there is no significant association between Pol η
expression and age, gender, primary tumor size, LN metastatic
status on the basis of such cases number. Although our results
did not find a significant association between Pol η expression
level and patient survival (OS and PFS), there is a trend
showing that higher Pol η expression is correlated with shorter
survival. There are several limitations to our study. First, the
Pol η staining was done on selected blocks, which might not
represent the status of the entire tumor tissue. Head and neck
squamous cell carcinoma is well known for its tumor
heterogeneity [57]. Indeed, we did find that Pol η expression
varied within same tumor. Second, our current study was
based on a retrospective analysis on a relatively small size of
samples over a long period (1989-2007). During the study
period, advances in treatment and supportive care could have
impact on the survival outcomes, thus affected the statistical
significance in our study. A well-designed prospective study
with extensive sampling is needed to validate the results with
more homogeneous and a larger number of patients.
In conclusion, the findings of the present study indicate that
immunohistochemical staining may be a useful tool in
evaluating the expression level of Pol η. Our results also
suggested the potential for using the basal Pol η expression
level in HNSCC as a predictive marker for platinum efficacy.
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